Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amplia Therapeutics ( (AU:ATX) ) has issued an announcement.
Amplia Therapeutics Limited announced the issuance of 1,000,000 ordinary shares following the exercise of options, which will align with existing shares. This move is part of their ongoing efforts to advance their pipeline, including the development of narmafotinib (AMP945), a promising FAK inhibitor currently in a Phase 2a trial for pancreatic cancer. The ACCENT trial is exploring the efficacy of narmafotinib in combination with standard chemotherapy, potentially enhancing treatment outcomes for patients with advanced pancreatic cancer.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for treating cancer and fibrosis. The company is particularly focused on fibrotic cancers such as pancreatic and ovarian cancer, and FAK’s role in chronic diseases like idiopathic pulmonary fibrosis.
Average Trading Volume: 6,618,883
Technical Sentiment Signal: Buy
Current Market Cap: A$110.8M
For an in-depth examination of ATX stock, go to TipRanks’ Overview page.